Dietary soya lecithin decreases plasma triglyceride levels and inhibits collagen- and ADP-induced platelet aggregation

1986 ◽  
Vol 35 (1) ◽  
pp. 31-39 ◽  
Author(s):  
J.Gerald Brook ◽  
Shai Linn ◽  
Michael Aviram
Nephron ◽  
1984 ◽  
Vol 38 (2) ◽  
pp. 120-124 ◽  
Author(s):  
Arthur Weschler ◽  
Michael Aviram ◽  
Moshe Levin ◽  
Ori S. Better ◽  
Gerald Brook

1983 ◽  
Vol 64 (1) ◽  
pp. 91-99 ◽  
Author(s):  
T. A. B. Sanders ◽  
Farah Roshanai

1. Five healthy subjects took a daily supplement of 20 ml of linseed oil for 2 weeks. After a break of at least 6 weeks, the same subjects took a similar amount of MaxEPA (a fish oil fraction) for 2 weeks. The linseed oil supplement provided 9.38 g of linolenic acid (18:3 ω3) and the MaxEPA supplement provided 3.03 g of eicosapentaenoic acid (20:5 ω3) and 2.93 g of docosahexaenoic acid (22:6 ω3). The effects of the supplements on plasma lipid concentrations and on the fatty acid composition of platelet phosphoglycerides were studied. 2. In a second experiment, five male subjects took 5, 10 and 20 g of MaxEPA/day in random order for 3 week periods; each experimental period was separated by a break of at least 6 weeks. These doses of MaxEPA provided 0.83, 1.67 and 3.33 g of 20:5 ω3 and 0.80, 1.61 and 3.22 g 22:6 ω3 respectively. The effects of these supplements on plasma lipid concentrations, the fatty acid composition of platelet phosphoglycerides, template bleeding time and platelet aggregation induced by collagen and the prostaglandin analogue compound U46619 were studied. 3. In the platelet lipids, the proportion of 20:5 ω3 was increased by the 20 ml linseed oil supplement but the increase was small compared with the increase brought about by even 5 g of MaxEPA/day. The proportion of arachidonic acid (20:4 ω3) was substantially decreased by the MaxEPA supplement but not by the linseed oil supplement. The ratio of 20:4 ω6/20:5 ω3 fell from 32:1 in the control periods to 11:1 with 5 g, 7:1 with 10 g and 5:1 with 20 g of MaxEPA/day. The MaxEPA supplement also led to increases in the proportions of 22:5 ω3 and 22:6 ω3 and decreases in those of 20:3 ω6 and 22:4 ω6. 4. Bleeding times tended to be prolonged with the MaxEPA supplement but did not follow any dose-dependent trend. Platelet aggregation induced by both collagen and compound U46619 was not inhibited in vitro. 5. Plasma triglyceride concentrations were lowered by the MaxEPA supplement but not by the linseed oil supplement. Plasma triglyceride concentrations were substantially lowered by 10 g and 20 g of MaxEPA/day. Total plasma cholesterol concentrations were slightly lowered and HDL cholesterol concentrations were slightly increased by 20 g of MaxEPA/day. No other significant differences were noted.


Author(s):  
W. H. Zucker ◽  
R. G. Mason

Platelet adhesion initiates platelet aggregation and is an important component of the hemostatic process. Since the development of a new form of collagen as a topical hemostatic agent is of both basic and clinical interest, an ultrastructural and hematologic study of the interaction of platelets with the microcrystalline collagen preparation was undertaken.In this study, whole blood anticoagulated with EDTA was used in order to inhibit aggregation and permit study of platelet adhesion to collagen as an isolated event. The microcrystalline collagen was prepared from bovine dermal corium; milling was with sharp blades. The preparation consists of partial hydrochloric acid amine collagen salts and retains much of the fibrillar morphology of native collagen.


Planta Medica ◽  
2008 ◽  
Vol 74 (09) ◽  
Author(s):  
M Dell'Agli ◽  
R Fagnani ◽  
G Galli ◽  
O Maschi ◽  
E de Fabiani ◽  
...  

1998 ◽  
Vol 79 (01) ◽  
pp. 211-216 ◽  
Author(s):  
Lysiane Hilbert ◽  
Claudine Mazurier ◽  
Christophe de Romeuf

SummaryType 2B of von Willebrand disease (vWD) refers to qualitative variants with increased affinity of von Willebrand factor (vWF) for platelet glycoprotein Ib (GPIb). All the mutations responsible for type 2B vWD have been located in the A1 domain of vWF. In this study, various recombinant von Willebrand factors (rvWF) reproducing four type 2B vWD missense mutations were compared to wild-type rvWF (WT-rvWF) for their spontaneous binding to platelets and their capacity to induce platelet activation and aggregation. Our data show that the multimeric pattern of each mutated rvWF is similar to that of WT-rvWF but the extent of spontaneous binding and the capacity to induce platelet activation and aggregation are more important for the R543Q and V553M mutations than for the L697V and A698V mutations. Both the binding of mutated rvWFs to platelets and platelet aggregation induced by type 2B rvWFs are inhibited by monoclonal anti-GPIb and anti-vWF antibodies, inhibitors of vWF binding to platelets in the presence of ristocetin, as well as by aurin tricarboxylic acid. On the other hand, EDTA and a monoclonal antibody directed against GPIIb/IIIa only inhibit platelet aggregation. Furthermore, the incubation of type 2B rvWFs with platelets, under stirring conditions, results in the decrease in high molecular weight vWF multimers in solution, the extent of which appears correlated with that of plasma vWF from type 2B vWD patients harboring the corresponding missense mutation. This study supports that the binding of different mutated type 2B vWFs onto platelet GPIb induces various degrees of platelet activation and aggregation and thus suggests that the phenotypic heterogeneity of type 2B vWD may be related to the nature and/or location of the causative point mutation.


1998 ◽  
Vol 79 (06) ◽  
pp. 1184-1190 ◽  
Author(s):  
Yoshiaki Tomiyama ◽  
Shigenori Honda ◽  
Kayoko Senzaki ◽  
Akito Tanaka ◽  
Mitsuru Okubo ◽  
...  

SummaryThis study investigated the difference of [Ca2+]i movement in platelets in response to thrombin and TRAP. The involvement of αIIbβ3 in this signaling was also studied. Stimulation of platelets with thrombin at 0.03 U/ml caused platelet aggregation and a two-peak increase in [Ca2+]i. The second peak of [Ca2+]i, but not the first peak was abolished by the inhibition of platelet aggregation with αIIbβ3 antagonists or by scavenging endogenous ADP with apyrase. A cyclooxygenase inhibitor, aspirin, and a TXA2 receptor antagonist, BM13505, also abolished the second peak of [Ca2+]i but not the first peak, although these regents did not inhibit aggregation. Under the same assay conditions, measurement of TXB2 demonstrated that αIIbβ3 antagonists and aspirin almost completely inhibited the production of TXB2. In contrast to thrombin-stimulation, TRAP caused only a single peak of [Ca2+]i even in the presence of platelet aggregation, and a high level of [Ca2+]i increase was needed for the induction of platelet aggregation. The inhibition of aggregation with αIIbβ3 antagonists had no effect on [Ca2+]i change and TXB2 production induced by TRAP. Inhibition studies using anti-GPIb antibodies suggested that GPIb may be involved in the thrombin response, but not in the TRAP. Our findings suggest that low dose thrombin causes a different [Ca2+]i response and TXA2 producing signal from TRAP. Endogenous ADP release and fibrinogen binding to αIIbβ3 are responsible for the synthesis of TXA2 which results in the induction of the second peak of [Ca2+]i in low thrombin- but not TRAP-stimulated platelets.


Sign in / Sign up

Export Citation Format

Share Document